Vanda Pharmaceuticals (NASDAQ: VNDA) sets FDA framework on HETLIOZ, tradipitant

Rhea-AI Filing Summary

Vanda Pharmaceuticals Inc. reported that it has reached a collaborative framework with the U.S. Food and Drug Administration to resolve certain disputes involving its drugs HETLIOZ® (tasimelteon) and tradipitant. This means the company and the FDA have agreed on a structured approach to address outstanding regulatory disagreements related to these products.

The company announced this development in a press release dated October 1, 2025, which is referenced as an exhibit. While specific terms or outcomes are not described here, the framework focuses on moving toward resolution of the disputes regarding these two drugs.

Insights

Biopharma regulatory analyst

Vanda and FDA agree on a framework to address drug disputes.

Vanda Pharmaceuticals Inc. states that it has reached a collaborative framework with the U.S. Food and Drug Administration to resolve certain disputes concerning HETLIOZ® (tasimelteon) and tradipitant. This indicates that the company and the agency have aligned on a process for addressing those regulatory issues, even though specific details are not described here.

For a drug-focused company, disputes with the FDA around key products can be significant, so having an agreed framework is an important procedural step. The actual business impact will depend on how the disputes are ultimately resolved, which is not outlined in this summary.

The press release dated October 1, 2025, is incorporated by reference as an exhibit and should contain the operational and regulatory details. Subsequent company communications and filings will show whether this framework leads to outcomes that affect HETLIOZ® and tradipitant’s regulatory status or commercial prospects.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001347178FALSE00013471782025-10-012025-10-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1, 2025

VANDA PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its charter)

Delaware

001-34186

03-0491827

(State or other jurisdiction of incorporation)

(Commission File No.)

(IRS Employer Identification No.)

2200 Pennsylvania Avenue NW

Suite 300E

Washington, DC 20037

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (202) 734-3400

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001 per share			VNDA			The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

Item 8.01. Other Events.

On October 1, 2025, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release announcing that it had reached a collaborative framework with the U.S. Food and Drug Administration for the resolution of certain disputes regarding Vanda’s drugs, HETLIOZ® (tasimelteon) and tradipitant.

The full text of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.						Description
99.1						Press release of Vanda Pharmaceuticals Inc. dated October 1, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:

October 1, 2025

VANDA PHARMACEUTICALS INC.

By:

/s/ Timothy Williams

Name:

Timothy Williams

Title:

Senior Vice President, General Counsel and Secretary

FAQ

What did Vanda Pharmaceuticals Inc. (VNDA) announce regarding the FDA?

Vanda Pharmaceuticals Inc. announced that it has reached a collaborative framework with the U.S. Food and Drug Administration to resolve certain disputes related to its drugs HETLIOZ® (tasimelteon) and tradipitant.

Which Vanda drugs are involved in the FDA dispute framework?

The collaborative framework with the U.S. Food and Drug Administration concerns disputes involving Vanda’s drugs HETLIOZ® (tasimelteon) and tradipitant.

How was the FDA framework announcement by Vanda communicated?

Vanda Pharmaceuticals Inc. communicated the announcement through a press release dated October 1, 2025, which is attached as Exhibit 99.1 and incorporated by reference.

Does the filing describe the specific terms of Vanda’s framework with the FDA?

The content states that a collaborative framework has been reached with the U.S. Food and Drug Administration but does not describe the specific terms or outcomes of that framework.

What SEC form did Vanda Pharmaceuticals Inc. (VNDA) use for this announcement?

Vanda Pharmaceuticals Inc. used a Form 8-K to report that it had reached a collaborative framework with the U.S. Food and Drug Administration regarding disputes over HETLIOZ® and tradipitant.

What exhibit is attached to Vanda’s Form 8-K about the FDA framework?

The Form 8-K attaches Exhibit 99.1, which is a press release of Vanda Pharmaceuticals Inc. dated October 1, 2025, and Exhibit 104, the cover page interactive data file.